Alterity Therapeutics Presents New bioMUSE Study Data

Ticker: PRNAF · Form: 6-K · Filed: May 31, 2024 · CIK: 1131343

Alterity Therapeutics Ltd 6-K Filing Summary
FieldDetail
CompanyAlterity Therapeutics Ltd (PRNAF)
Form Type6-K
Filed DateMay 31, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: clinical-data, filing-update, registration-statement

TL;DR

Alterity dropped new data from its bioMUSE study today via a 6-K filing.

AI Summary

Alterity Therapeutics Limited filed a Form 6-K on May 31, 2024, to incorporate by reference a webcast presentation of new data from its bioMUSE Natural History Study. The filing is related to ongoing registration statements on Form S-8 and Form F-3.

Why It Matters

This filing provides investors with updated information on Alterity's clinical development programs, specifically the bioMUSE study, which could impact the company's future valuation.

Risk Assessment

Risk Level: medium — The filing relates to clinical trial data, which inherently carries risks associated with drug development and regulatory approval.

Key Players & Entities

  • Alterity Therapeutics Limited (company) — Registrant
  • bioMUSE Natural History Study (study) — Clinical trial data presented
  • May 2024 (date) — Reporting period for Form 6-K
  • May 31, 2024 (date) — Filing date of Form 6-K

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is being filed to incorporate by reference Exhibit 99.1, which is a webcast presentation of new data from the bioMUSE Natural History Study.

What specific study is highlighted in the incorporated exhibit?

The incorporated exhibit (99.1) presents new data from the bioMUSE Natural History Study.

Which registration statements is this Form 6-K being incorporated into?

This Form 6-K is being incorporated by reference into Alterity Therapeutics Limited's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).

What is the principal executive office address of Alterity Therapeutics Limited?

The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.

What is the SIC code for Alterity Therapeutics Limited?

The Standard Industrial Classification (SIC) code for Alterity Therapeutics Limited is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 194 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-05-30 20:29:45

Filing Documents

From the Filing

OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Webcast Today - New Data from bioMUSE Natural History Study 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: May 30, 2024 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.